



30th July 2020

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Re: Outcome of the Board Meeting

Dear Sir/Madam,

At the Board meeting held today, the Board has inter alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2020. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

- i. Press Release being issued on the Results for the quarter ended 30th June 2020;
- ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2020;
- iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2020;
- iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2020;
- v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2020;
- vi. Investors' presentation.

Kindly note that the meeting of the Board of Directors commenced at 12.30 p.m. and concluded at 1.40 p.m. and take the above on your records.

Kindly take the above on your records.

Thanking You,

Yours faithfully,

GAURANG SHAH

AVP - Legal & Company Secretary

Encl.: a/a

PAT up by 29%

(1st Quarter FY 2021 Consolidated Results)

Mumbai, 30th July, 2020: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June 2020.

Q1 FY 2021 performance highlights (compared to Q1 FY 20)

- Income from operations at Rs. 668 cr. against Rs. 612 cr., up 9%.
- EBITDA at Rs. 223 cr. against Rs. 168 cr., up 33%; EBITDA at 33% of revenue.
- Profit after tax at Rs. 148 cr. against Rs. 115 cr. up 29%, PAT at 22% of revenue.

India

For Q1 FY 2021, India sales was Rs. 174 cr. (against Rs. 194 cr.), down 10%.

As per IQVIA MAT June 2020, we have posted healthy growth of 10% in Cardiology (segment growth of 12%), 5% in Ophthalmology (segment growth of 3%), 10% in Pain Management (segment growth of 5%) and de-growth of 3% in Dermatology (segment growth of 5%)

Exports

Q1 FY 2021, total export sales were Rs. 483 cr. (against Rs. 404 cr.) posting growth of 19%. Segment wise break-up given below:

Emerging market branded generic	Sale was Rs. 271 cr. (against Rs. 221 cr.) posting 23% growth. Out of which: - Africa branded generic sale was Rs. 108 cr. (against Rs. 92 cr.) posting 17% growth. - Asia branded generic sale was Rs. 161 cr. (against Rs. 126 cr.) posting 28% growth.
US generic	Sale was Rs. 149 cr. (against Rs. 102 cr.) posting 46% growth. In US, during Q1 FY 2021, company received 5 ANDA final approval from US FDA. Out of 37 final ANDA approvals, we have commercialized 30 products. We hold 1 tentative approval and 19 ANDAs are awaiting US FDA approval. Company plans to file 10 to 12 ANDAs during this financial year.
Africa Institution	Sale was Rs. 62 cr. (against Rs. 81 cr.) posting 23% de-growth.

R&D

During Q1 FY 2021, R&D expenses were Rs. 31 cr., 5% of operating income (Q1 FY 2020 Rs. 40 cr., 6% of operating income).

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centre is located at Mumbai. Company has 8 world class manufacturing facilities located in India and Mauritius.

For last 10 financial years, company has posted healthy performance with its consolidated total income growing at 20% CAGR and net profit at 28% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2020

Particulars	3 months ended			in Crore
	30-Jun-20	31-Mar-20	30-Jun-19	Year Ended
	Unaudited	Audited (Refer Note 7)	Unaudited	31-Mar-20
Income				
Revenue from operations	668.20	681.96	611.94	2,587.87
Other income	13.12	56.69	7.64	92.19
Total Income	681.32	738.65	619.58	2,680.06
Expenses				
Cost of materials consumed	153.87	173.53	124.18	560.33
Purchases of stock-in-trade	17.65	29.69	33.75	112.13
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(18.42)	(25.62)	(15.39)	(16.75)
Employee benefits expense	135.79	129.48	118.32	485.59
Finance costs	1.63	3.62	1.79	11.91
Depreciation and amortisation expense	28.02	26.04	22.78	95.72
Other expenses	156.09	223.54	182.70	763.24
Total Expenses	474.63	560.28	468.13	2,012.17
Profit before exceptional items and tax	206.69	178.37	151.45	667.89
Exceptional Item				
Exceptional Item (Refer note 5)	-	2.51	-	3.92
Profit before tax	206.69	175.86	151.45	663.97
Tax Expense				
Current Tax (net)	53.13	49.53	33.20	186.35
Deferred Tax (net)	5.80	(2.83)	3.62	9.92
Profit after tax	147.76	129.16	114.63	467.70
Other Comprehensive Income (OCI)				
Items that will be reclassified subsequently to profit or loss	1.42	5.21	(0.98)	8.11
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(0.98)	(0.49)	(0.49)	(3.92)
Income tax relating to items that will not be reclassified to profit or loss	0.34	0.17	0.17	1.37
Other Comprehensive Income for the year, net of tax	0.78	4.89	(1.30)	5.56
Total Comprehensive Income for the period	148.54	134.05	113.33	473.26
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.54	17.54	17.54	17.54
Other Equity				2,581.33
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	16.93	14.80	13.14	53.60
Diluted - in ₹	16.93	14.80	13.14	53.60

Notes :

- The above results have been reviewed by Audit Committee and approved by Board of Directors at their meeting held on 30 July 2020.
- Statutory Auditors have expressed an unqualified review opinion for quarter ended 30 June 2020.
- The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- The Group has taken into account the possible impacts of COVID-19 in preparation of the consolidated financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The actual impact of COVID-19 in coming quarters may be different from that of this quarter, depending on how the situation evolves globally. The Group will continue to closely monitor future economic conditions to ensure business continuity.
- Exceptional item in 31 March 2020 quarter and year end 31 March 2020 represents loss due to a fire and other events at Guwahati plant net of minimum insurance claim receivable. In addition to the claim that has been settled, the Company has received ₹ 16 crores against the pending claims. The survey is in progress and accordingly no further amounts claimed have been recognised pending the conclusion of the survey.
- During the quarter Nil equity shares (previous quarter 1,000) of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ Nil (previous quarter ₹ 2,000) and securities premium account by ₹ Nil crores (previous quarter ₹ 0.12 crores).
- The figures for the quarter ended 31 March 2020 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter ended 31 December 2019.
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

By order of the Board
For Ajanta Pharma Ltd.

**SREEJA
RAJASEKHA
RAN MARAR**

Digitally signed by
SREEJA RAJASEKHARAN
MARAR
Date: 2020.07.30
13:22:47 +05'30'

**Yogesh
Mannalal
Agrawal**

Digitally signed by
Yogesh Mannalal
Agrawal
Date: 2020.07.30
12:58:18 +05'30'

Yogesh M. Agrawal
Managing Director

Mumbai, 30 July 2020

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on unaudited quarterly consolidated financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015

To Board of Directors of Ajanta Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Ajanta Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30 June 2020 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Ajanta Pharma (Mauritius) Limited	Subsidiary
Ajanta Pharma USA Inc.	Subsidiary
Ajanta Pharma Philippines Inc.	Subsidiary
Ajanta Pharma Nigeria Limited	Subsidiary
Ajanta Pharma (Mauritius) International Limited	Subsidiary

Ajanta Pharma Limited

Limited Review Report on unaudited quarterly consolidated financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015 (Continued)

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial results of 2 subsidiaries which have not been reviewed, whose interim financial results reflect total revenues of Rs 54.58 crore, total net profit after tax of Rs 6.65 crore and total comprehensive income of Rs 6.65 crore for the quarter ended 30 June 2020, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Mumbai
30 July 2020

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W-100022
SREEJA
RAJASEKHAR
AN MARAR
Digitally signed by
SREEJA RAJASEKHARAN
MARAR
Date: 2020.07.30
13:19:37 +05'30'
Sreeja Marar
Partner
Membership No: 111410
UDIN: 20111410AAAABJ4412

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2020

` in Crore

Particulars	3 months ended			Year Ended
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
	Unaudited	Audited (Refer Note 7)	Unaudited	Audited
Income				
Revenue from operations	560.85	560.68	545.74	2,196.42
Other income	13.10	54.10	39.62	184.20
Total Income	573.95	614.78	585.36	2,380.62
Expenses				
Cost of materials consumed	153.32	172.29	123.79	556.22
Purchases of stock-in-trade	22.59	22.99	28.63	98.73
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(25.53)	(24.34)	11.07	9.02
Employee benefits expense	123.82	117.26	107.37	437.82
Finance costs	1.20	2.93	1.09	9.10
Depreciation and amortisation expense	26.86	24.89	21.71	91.29
Other expenses	113.22	166.63	135.25	561.85
Total Expenses	415.48	482.65	428.91	1,764.03
Profit before exceptional items and tax	158.47	132.13	156.45	616.59
Exceptional Item				
Exceptional Item (Refer note 5)	-	2.51	-	3.92
Profit before tax	158.47	129.62	156.45	612.67
Tax Expense				
Current Tax (net)	38.07	42.49	28.88	168.09
Deferred Tax (net)	4.71	(1.38)	3.97	3.45
Profit after tax	115.69	88.51	123.60	441.13
Other Comprehensive Income (OCI)				
Items that will not be reclassified subsequently to profit or loss	(0.98)	(0.49)	(0.49)	(3.92)
Income tax relating to items that will not be reclassified to profit or loss	0.34	0.17	0.17	1.37
Other Comprehensive Income for the year, net of tax	(0.64)	(0.32)	(0.32)	(2.55)
Total Comprehensive Income for the period	115.05	88.19	123.28	438.58
Paid-up Equity Share Capital (Face value of ` 2 each)	17.54	17.54	17.54	17.54
Other Equity				2,443.76
Earnings Per Share (Face value of ` 2 each)				
Basic - in `	13.26	10.14	14.17	50.55
Diluted - in `	13.26	10.14	14.16	50.55

Notes :

1. The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2020.

2. Statutory Auditors have expressed an unqualified review opinion for quarter ended 30 June 2020.

3. Other income includes :

	3 months ended			Year Ended
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
Dividend from subsidiaries (` in Crore)	-	-	34.71	101.30

4. The Company has taken into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Company has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The actual impact of COVID-19 in coming quarters may be different from that of this quarter, depending on how the situation evolves globally. The Company will continue to closely monitor future economic conditions to ensure business continuity.

5. Exceptional item in 31 March 2020 quarter and year end 31 March 2020 represents loss due to a fire and other events at Guwahati plant net of minimum insurance claim receivable. In addition to the claim that has been settled, the Company has received ` 16 crores against the pending claims. The survey is in progress and accordingly no further amounts claimed have been recognised pending the conclusion of the survey.

6. During the quarter Nil equity shares (previous quarter 1,000) of ` 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ` Nil (previous quarter ` 2,000) and securities premium account by ` Nil crores (previous quarter ` 0.12 crores).

7. The figures for the quarter ended 31 March 2020 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter ended 31 December 2019.

8. The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

9. The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh
Mannalal
Agrawal

Yogesh M. Agrawal
Managing Director

**SREEJA
RAJASEKHAR
AN MARAR**

Digitally signed by
SREEJA RAJASEKHARAN
MARAR
Date: 2020.07.30
13:21:46 +05'30'

Mumbai, 30 July 2020

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on unaudited quarterly standalone financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015

To the Board of Directors of Ajanta Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Ajanta Pharma Limited ('the Company') for the quarter ended 30 June 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Ajanta Pharma Limited

Limited Review Report on unaudited quarterly standalone financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015 (Continued)

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No. 101248W/W-100022

SREEJA
RAJASEKHARAN
MARAR

Digitally signed by SREEJA
RAJASEKHARAN MARAR
Date: 2020.07.30 13:20:11
+05'30'

Sreeja Marar

Partner

Mumbai
30 July 2020

Membership No. 111410
UDIN 20111410AAAABI2582



INVESTOR PRESENTATION

Q1 FY 2021

30th July 2020






Content

01 India Business

02 Global Business

03 Infrastructure

04 Financial Highlights



India Business

India Branded Generics



15

Divisions

For 4 Segments

3,000

M R s

Building Efficiency

270+

Product Basket

1st to
Market

Products

Continue to Focus on 4 Therapeutic Segments



Cardiology

.....
Growth slows temporarily, expected to bounce back



Ophthalmology

.....
2nd largest in India & still growing above Industry



Dermatology

.....
Covid impact resulted in de-growth, taking remedial steps



Pain
Management


.....
Consistently performing well, gained 2 ranks

Segment Growth




Pharma Market

■ IPM ■ Ajanta Pharma




Cardiology

■ IPM ■ Ajanta Pharma




Ophthalmology

■ IPM ■ Ajanta Pharma




Dermatology

■ IPM ■ Ajanta Pharma



Pain Management

■ IPM ■ Ajanta Pharma




IPM = Indian Pharmaceutical Market
Source: Iqvia, June MAT 2020

Industry Growth




March 2017

■ IPM ■ Ajanta Pharma




March 2018

■ IPM ■ Ajanta Pharma




March 2019

■ IPM ■ Ajanta Pharma




March 2020

■ IPM ■ Ajanta Pharma





June 2020

■ IPM ■ Ajanta Pharma



IPM = Indian Pharmaceutical Market
Source: Iqvia, June MAT 2020

India Sales



IPM - Ranking




	March 2005	June 2019	June 2020
Ophthalmology	28	2	2
Dermatology	98	14	15
Cardiology	38	15	17
Pain Mgmt.	NA	41	36
Ajanta	88	31	29

Source: Iqvia, June MAT 2020



Global Business

Global Presence



Map not to scale, only for illustration purpose

Branded Generic Business in Emerging Markets



Africa

Product Registrations

1,000+

Major Therapeutic Segments

Anti-Malaria
Antibiotics
Gynecology
Vitamins
Cardiology
Ophthalmology
Pain Management

Asia

Product Registrations

299

Therapeutic Segments

Cardiology
Pain Management
Antibiotics
Gastroenterology
Anti-Histamines
Respiratory
Neurology

USA



38

37 - Final Approval
1 - Tentative
5 in Q1 FY 2021

19

Under Approval

~10-12

Filing Target


30 Products
on shelf

More product
launches
in FY 2021


Steady gain in
market share

Focus on sound
execution for
customer delight

Export Sales – Q1 (Consolidated)



Total Consolidated Sales – Q1





Rs. cr.

	Q1 FY 2020	Q1 FY 2021	Gwth
India	194	174	(10%)
Exports	404	483	19%
Total Sales	598	657	10%



Infrastructure

Research & Development



Enabling Infrastructure

Formulation Manufacturing

- 3 facilities at Aurangabad, Maharashtra
- 1 facility at Dahej, Gujarat
- 1 facility at Guwahati, Assam, Ophthalmic bloc to commence operation in Q2 FY21
- 1 facility at Pithampur, Madhya Pradesh (newly commissioned)
- 1 facility at Mauritius

API Manufacturing

- 1 facility at Waluj, Aurangabad, Maharashtra (Captive Consumption)



Pitampur facility





Financial Highlights

P&L Synopsis – Q1 FY 2021 (Consolidated)



Rs. cr.	Q1 FY 2020	%	Q1 FY 2021	%	% Growth
Exports	404	66%	483	72%	19%
Domestic	194	32%	174	26%	(10%)
Other Op. Income	14	2%	11	2%	(14%)
Income from Operations	612		668		9%
EBITDA	168	28%	223	33%	33%
PBT	151	25%	207	31%	36%
PAT	115	19%	148	22%	29%
Total Comprehensive Income	113	19%	149	22%	31%

Detailed P&L – Q1 FY 2021 (Consolidated)




Rs. cr.	Q1 FY 2020	% to IO	Q1 FY 2021	% to IO
Income from Operations	612		668	
Other Income	8	1%	13	2%
Total Income	620		681	
Materials consumed	143	23%	152	23%
Employee Benefit	118	19%	136	20%
Finance Cost	2	0%	2	0%
Depreciation	23	4%	28	4%
Other Expenses	184	30%	156	23%
Total Expenses	469	76%	474	70%
Profit before Tax	151	25%	207	31%
Tax Expense	37	6%	59	9%
Net Profit	115	19%	148	22%
Other Comprehensive Income	(1)	(1%)	1	0%
Total Comprehensive Income	113	19%	149	22%
EBITDA	168	28%	223	33%


5 Year Track Record (Consolidated)







Consolidated Total Income
(Rs. cr.)







PAT (Rs. cr.) & PAT Margin (%)



5 Year Track Record (Consolidated)




5 Year Track Record (Consolidated)




5 Year Track Record (Consolidated)




Total Debt / Equity
(Ratio.)



Receivable Days
(Nos.)




Inventory Days
(Nos.)



Payable Days
(Nos.)



CSR - Covid Assistance



Rs. 7 cr.

**Ajanta Pharma family
contributes in
fight against COVID**

Rs. 2 cr. - PM CARES fund

Rs. 4 cr. - State Govt. & BMC

1. Masks - 7 Lacs +
2. Sanitizers - 1.3 Lac+
3. Food – 1.25 Lacs+

Rs. 1 cr. Contribution by
Ajantaitees 1 day salary



LOCATION:

**MAHALAXMI
RACECOURSE
& NSCI DOME :**

This entire project has been done under the guidance and coordination of Shri Aditya Thackeray.

The Parking lot of racecourse at Worli and a part of the NSCI Dome has been allocated for creating this facility.



CSR - Covid Assistance



Distributed ration to needy, sanitizers & masks to Govt. hospitals, jail, etc.

Thank You

For more information please visit our website:

www.ajantapharma.com

For regular updates follow us on twitter

www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal - 022-66061377

rajeev.agarwal@ajantapharma.com

Abhineet Kumar – 022-66061814

abhineet.kumar@ajantapharma.com

Ajanta House, Charkop, Kandivli (W), Mumbai 400 067

CIN No. - L24230MH1979PLC022059

DISCLAIMER



This presentation may include certain 'forward looking statements', based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

The Company disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

This material is used during oral presentation; it is not a complete record of the discussion.